Phosphagenics Sp ADR (PPGNY) 0.5640 $PPGNY Acne Vulgaris

New Post Public Reply Private Reply Replies (0) Message Board

Sep 12, 2015 at 1:14 AM

Phosphagenics Sp ADR (PPGNY) 0.5640 $PPGNY

Acne Vulgaris Pipeline Review 2015 - 40 Companies & 53 Drug Profiles
M2 - Tue Jul 21, 10:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mtb2tv/acne_vulgaris) has announced the addition of the "Acne Vulgaris - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acne Vulgaris, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acne Vulgaris and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Advancell - Allergan, Inc. - AndroScience Corporation - Biomar Microbial Technologies - Braintree Laboratories, Inc. - Brickell Biotech, Inc. - Celtaxsys, Inc. - Cosmo Pharmaceuticals S.p.A - Cutanea Life Sciences - Delenex Therapeutics AG - Deltanoid Pharmaceuticals Inc. - Dermira Inc. - ELORAC, Inc. - Ensoltek Co., Ltd. - Foamix Pharmaceuticals Ltd. - Galderma S.A. - GlaxoSmithKline plc - Helix BioMedix, Inc. - Hovione FarmaCiencia SA - Kasiak Research Pvt. Ltd. - Lee's Pharmaceutical Holdings Limited - Maruho Co., Ltd. - Nabriva Therapeutics AG - Novabiotics Ltd - Novan, Inc. - OrigImm e.U. - Paratek Pharmaceuticals, Inc. - Phosphagenics Limited - Photocure ASA - Provectus Biopharmaceuticals, Inc. - QLT Inc. - RestorGenex Corporation - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Telesso Technologies Limited - Thesan Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/mt...e_vulgaris
QLTI: 3.44 (unch), FOMX: 9.95 (-0.04), GSK: 40.26 (+0.02), PRTK: 23.33 (-0.36), AGN: 295.24 (+1.64), PVCT: 0.66 (+0.03), DERM: 27.46 (+1.03), NBRV: ()

Osteoarthritis Pain Pipeline Report 2015 - 26 Companies & 46 Drug Profiles
M2 - Fri Jul 10, 3:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w8bmth/osteoarthritis) has announced the addition of the "Osteoarthritis Pain - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Osteoarthritis Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoarthritis Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Actavis plc - Addex Therapeutics Ltd - Afferent Pharmaceuticals, Inc. - Akron Molecules AG - Amgen Inc. - Ampio Pharmaceuticals, Inc. - AnaMar AB - Antibe Therapeutics, Inc. - Astellas Pharma Inc. - Boehringer Ingelheim GmbH - Bone Medical Limited - Eli Lilly and Company - Flexion Therapeutics, Inc. - Grunenthal GmbH - iCeutica, Inc. - Iroko Pharmaceuticals, LLC - Nektar Therapeutics - Nuvo Research Inc. - Pfizer Inc. - Phosphagenics Limited - Pozen, Inc. - Purdue Pharma L.P. - Regeneron Pharmaceuticals, Inc. - Rottapharm SpA - Teva Pharmaceutical Industries Limited Drug Profiles - (lidocaine tetracaine) - A-889425 - AAT-008 - ADX-71441 - AF-219 - AKR-202 - AMAP-102 - Ampion - AQU-010 - AS-288640100 - ATB-346 - BI-1026706 - calcitonin - cebranopadol - celecoxib - CGS-125 - CRB-0022 - CRB-0089 - duloxetine hydrochloride DR - ELS-130 - fasinumab - fulranumab - FX-005 - grapiprant - ibuprofen - ibuprofen - LY-2951742 - meloxicam - naproxen sodium - NEO-5024 - NEO-6860 - NKTR-181 - OLT-1177 - onabotulinumtoxin A - oxycodone ER For more information visit http://www.researchandmarkets.com/research/w8...oarthritis
FLXN: 23.42 (+0.14), PFE: 32.97 (+0.35), AMGN: 153.21 (+0.07), AMPE: 3.12 (+0.14), LLY: 81.80 (+0.96), NKTR: 12.24 (+0.79), TEVA: 63.66 (+1.62), ABBV: 59.35 (-0.23), POZN: 9.17 (+0.31), REGN: 533.30 (+2.08)

Complicated Skin And Skin Structure Infections (cSSSI) Therapeutics Pipeline Review, H1 2015 - 7 Companies & 11 Drug Profiles
M2 - Thu Jul 09, 10:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vw27k3/complicated_skin) has announced the addition of the "Complicated Skin And Skin Structure Infections (cSSSI) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Complicated Skin And Skin Structure Infections (cSSSI), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Complicated Skin And Skin Structure Infections (cSSSI) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Cempra, Inc. - CrystalGenomics, Inc. - Debiopharm International S.A. - Dong-A Socio Group - GlaxoSmithKline plc - Melinta Therapeutics, Inc - Phosphagenics Limited Drug Profiles - CG-400549 - Debio-1450 - Debio-1452 - delafloxacin - fusidic acid - GSK-2140944 - iclaprim mesylate - lanopepden - Small Molecule for Skin Infections - Small Molecules to Inhibit DHFR for Infectious Diseases - tedizolid phosphate For more information visit http://www.researchandmarkets.com/research/vw...cated_skin
GSK: 40.26 (+0.02), CEMP: 35.17 (+1.59)

Peripheral Neuropathic Pain - Pipeline Review, H1 2015
M2 - Mon Jun 29, 10:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9893bq/peripheral) has announced the addition of the "Peripheral Neuropathic Pain - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Peripheral Neuropathic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral Neuropathic Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - AnaBios Corporation - Astellas Pharma Inc. - Eli Lilly and Company - GW Pharmaceuticals plc - Nektar Therapeutics - Pfizer Inc. - Phosphagenics Limited - Sunovion Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/9893bq/peripheral
PFE: 32.97 (+0.35), LLY: 81.80 (+0.96), NKTR: 12.24 (+0.79)

Seborrhea Pipeline Review, H1 2015 - 4 Companies & 6 Drug Profiles
M2 - Fri Jun 12, 4:52AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pvb5km/seborrhea) has announced the addition of the "Seborrhea - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Seborrhea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Seborrhea and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Biomar Microbial Technologies - EpiPharm AG - Maruho Co., Ltd. - Phosphagenics Limited Drug Profiles - A-101 - EPI-SK14 - IB-07A081 - IB-07A085 - ketoconazole - lanoconazole For more information visit http://www.researchandmarkets.com/research/pvb5km/seborrhea

Dermatitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Apr 21, 10:31AM CDT
The report "Dermatitis - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Dermatitis. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/dermatitis-p...eport.html .
VTAE: 14.32 (+0.51), FOMX: 9.95 (-0.04), PVCT: 0.66 (+0.03), JNJ: 92.93 (+0.21), DERM: 27.46 (+1.03), ANAC: 141.14 (+1.10), XNCR: 16.39 (-0.49), REGN: 533.30 (+2.08), AQXP: 17.26 (+0.80), BMY: 59.22 (+0.47), GSK: 40.26 (+0.02), VRX.TO: 298.92 (-3.40), CBPO: 99.84 (+1.16), MRK: 52.09 (-0.63), CCXI: 6.40 (unch), CLTX: 2.18 (+0.06), CELGZ: 1.93 (+0.07), NVS: 96.55 (+0.28)

Seborrhea Therapeutic Pipeline Review H2 2014 Report at ReportsnReports.com
PRWeb - Fri Jan 02, 4:30PM CST
The report "Seborrhea Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Seborrhea. Seborrhea is a common skin problem. It causes a red, itchy rash and white scales. It particularly affects the sebaceous-gland-rich areas of skin such as scalp, face and torso. Seborrhoeic dermatitis symptoms appear gradually and usually the first signs are flaky skin and scalp. Adults of all ages may develop seborrhea, too, especially on the scalp and face. Complete Report is Available @ http://www.reportsnreports.com/reports/321896...-2014.html .
VRX.TO: 298.92 (-3.40)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Solidion Technology's Q3 Results: Strong Cash, EPS Growth

Solidion Makes Big Waves with Q3 Financial Performance Hot off the press, Solidion Technology, Inc. (NASDAQ: STI) has released its third quarter 2026 financial results, and let me tell you, it's a breath of fresh air for this advanced battery technology player. Maintaining a robust cash position and showcasing a stark contrast in earnings from last year, the company...

U.S. Money Reserve Earns Top Workplace Nod Again

Celebrating Another Year of Workplace Excellence Ah, the old adage: a company is only as good as its people. Well, U.S. Money Reserve seems to have taken that to heart, as they snag their second consecutive "Top Workplace" title in Austin. Now, it ain't every day you see a company score high marks on employee satisfaction, especially for two years in a row. But here they...

Stellus Capital Delivers Solid Q3 Amid Turbulent Times

Unpacking Stellus Capital's Latest Quarter Boy, Stellus Capital sure knows how to keep us on our toes. In a landscape where many are still reeling from the latest market tremors, they post some solid Q3 numbers for September 30, 2026. Not without its hiccups, but hey, who isn’t stumbling a bit right now? Financial Snapshot: Stability Amidst Uncertainty Stellus reported...

Guizhou's Mountain Conference Pushes Tourism Evolution

Climbing High: Guizhou's Tourism Summit The 2026 International Conference of Mountain Tourism and Outdoor Sports in Guizhou has kicked off with a heartfelt focus on merging natural allure with modern tourism. This isn't just another gathering; it's a powerhouse of international dialogue harbored right in China's dramatic landscape. Building on Unique Natural Assets...

Specialty1 Partners: Top Workplaces Triumph in 2026

Employees Crown Specialty1 Partners a Workplace Gem There are only a few things in the business world sweeter than being named a Top Workplace, and flying that banner proudly is exactly what Specialty1 Partners gets to do. Named a winner by the Houston Chronicle in 2026, this recognition is no regular accolade. It's built on the raw honesty that employee surveys provide,...

VILVA's Global Reach: Power Testing's Next Phase

A Power Play on Global Markets Taking a page from its relentless pursuit of quality and innovation, VILVA Electronics is bolstering its foothold on the international stage. Based in Shenzhen, this savvy player is reaching out for strategic partners like fishing for that perfect bite, hoping to reel in catches that understand the nitty-gritty of the local ponds—their...

O-I Glass Faces Class Action: Investor Implications

O-I Glass in Hot Water Over Misleading Statements I'll tell you, nothing gets my goat quite like uncovering deceptive practices in the corporate world. It seems O-I Glass, Inc. (NYSE: OI), might have played a fast one with its shareholders. The company is staring down the barrel of a class action lawsuit from Schall, Brown & Schwartz LLP, alleging they weren't entirely...

Summit Midstream's Q3 Financial Results Signal Growth

Summit Midstream Delivers Strong Q3 Results Good grief, you'd think the grease is sliding off the griddle with these numbers. Summit Midstream Corporation (NYSE:SMC) is putting up figures that ought to make even the most poker-faced of traders crack a smile. We've got a net income sitting pretty at $15.9 million, and an Adjusted EBITDA that's climbed up to $70.7 million....

Nevada Organic Phosphate Plans Share Consolidation

The Drill Down on Nevada Organic Phosphate's Strategic Moves There's a lot to unpack here as Nevada Organic Phosphate Inc. (CSE: NOP) rolls out its big game plan. They're looking to consolidate shares, flex their financial muscles, and maybe spray some high-octane fuel on their market positioning. Could be a smart move if they pull it off, but that's a big 'if' hanging in...

Higer Buses Debut in UK: Expansion on Full Throttle

Shifting Gears in the UK: Higer Enters the Fray You don't just waltz into the UK's bus and coach market without making some serious noise. Well, Higer is doing just that at Euro Bus Expo 2026. Birmingham's NEC turned into a stage for their showdown, where they unveiled three models: Azure 9, V12, and V10. The star of the show, the Azure 9, is tailored just for the Brits,...